GEO Accession viewer

NCBI > GEO > Accession Display

Not logged in | Login

GEO help: Mouse over screen elements for information.

Series GSE246282

Query DataSets for GSE246282

Status

Public on Oct 31, 2023

Title

Gene expression profiling of benign and matched tumour prostate tissue from patients diagnosed with prostate cacner (PCa)

Organism

Homo sapiens

Experiment type

Expression profiling by array

Summary

An integrated transcriptome-wide gene expression analysis, including differential gene expression analysis and weighted gene co-expression network analysis (WGCNA), was carried out based on transcriptomics data from a series of nine matched, histologically confirmed PCa and benign samples using the Affymetrix Clariom D Human array. The analysis identified a set of potential gene markers highly associated with tumor status (malignant vs. benign). We then used these genes to establish a minimal progression-free survival (PFS)-associated gene signature (GS) (PCBP1, PABPN1, PTPRF, DANCR, and MYC) using the least absolute shrinkage and selection operator (LASSO) and stepwise multivariate Cox regression analyses from The Cancer Genome Atlas prostate adenocarcinoma (TCGA-PRAD) dataset. Our signature was able to predict PFS over 1, 3, and 5 years in the TCGA-PRAD dataset, with an area under the curve (AUC) of 0.64–0.78, and our signature remained as a prognostic factor independent of age, Gleason score, and pathological T and N stages. A nomogram combining the signature and Gleason score demonstrated improved predictive capability for PFS (AUC: 0.71–0.85) and was superior to the Cambridge Prognostic Group (CPG) model alone and some conventionally used clinicopathological factors in predicting PFS. In conclusion, we have identified and validated a novel five-gene signature and established a nomogram that effectively predicted PFS in patients with PCa. These findings may improve current prognostic tools for PFS and contribute to clinical decision-making in PCa treatment.

Overall design

A total of 18 samples were analysed (nine matched pairs of malignant PCa and benign samples)

Contributor(s)

Mou Z, Spencer J, Knight B, John J, McCullagh P, McGrath JS, Harries LW

Citation(s)

37924098

Submission date

Oct 26, 2023

Last update date

Nov 16, 2023

Contact name

Zhuofan Mou